Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…
Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in Tennessee: - The West Clinic (East Campus) — Germantown, Tennessee
- Nashville General Hospital at Meharry — Nashville, Tennessee
Phase 2 Recruiting NIH
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectab…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06050252
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Tennessee: - Tennessee Oncology — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Tennessee: - Research Site 136 — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Tennessee: - Sarah Cannon Research Institute — Nashville, Tennessee
- Vanderbilt Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Tennessee: - Saint Jude Children's Research Hospital — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Network
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come b…
Sponsor: Children's Oncology Group
NCT ID: NCT06620302
Sites in Tennessee: - Saint Jude Children's Research Hospital — Memphis, Tennessee
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Tennessee: - Tn Gynecologic Oncology Group, Llc — Chattanooga, Tennessee
- The West Clinic — Germantown, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04524871
Sites in Tennessee: - Sarah Cannon Research Institute / Tennessee Oncology — Nashville, Tennessee
Phase 2 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced un…
Sponsor: Replimune, Inc.
NCT ID: NCT05733598
Sites in Tennessee: - The West Clinic — Germantown, Tennessee
- University of Tennessee Medical Center — Knoxville, Tennessee
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07291076
Sites in Tennessee: - Local Institution - 0022 — Nashville, Tennessee
- Local Institution - 0102 — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Tennessee: - Sarah Cannon Research Institute — Nashville, Tennessee
Phase 2 Recruiting Industry
RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophos…
Sponsor: Riboscience, LLC.
NCT ID: NCT07175441
Sites in Tennessee: - Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Academic/Other
This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent and young…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05468359
Sites in Tennessee: - Methodist Le Bonheur Healthcare — Germantown, Tennessee
- St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Tennessee: - Exelixis Clinical Site #3 — Nashville, Tennessee
Phase 1 Recruiting Industry
This is a multicenter, randomized, double-blind, parallel-controlled, phase I clinical study to evaluate the PK characteristics, safety, efficacy, and immunogenicity of HLX13 and US-sourced YERVOY® in patients with unresectable hepatocellu…
Sponsor: Shanghai Henlius Biotech
NCT ID: NCT07176650
Sites in Tennessee: - HCA Research Institute, LLC — Brentwood, Tennessee
Phase 1 Recruiting Industry
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths. The purpose of this study is to assess adverse events a…
Sponsor: AbbVie
NCT ID: NCT06858813
Sites in Tennessee: - SCRI Oncology Partners /ID# 272750 — Nashville, Tennessee
Phase 1 Recruiting Industry
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocel…
Sponsor: Tyra Biosciences, Inc
NCT ID: NCT06915753
Sites in Tennessee: - Sarah Cannon Research Institute Oncology Partners — Nashville, Tennessee
Phase 1 Recruiting Industry
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101wil…
Sponsor: Angiex, Inc.
NCT ID: NCT06440005
Sites in Tennessee: - Sarah Cannon Research Center — Nashville, Tennessee
Phase 1 Recruiting Industry
This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizuma…
Sponsor: BeOne Medicines
NCT ID: NCT06427941
Sites in Tennessee: - Scri Oncology Partners — Nashville, Tennessee
Phase 1 Recruiting Academic/Other
This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the primary site and/or metastatic deposits is critical for achieving a cure. An optima…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04084067
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Tennessee: - Massive Bio SYNERGY-AI site — Memphis, Tennessee
- Massive Bio SYNERGY-AI site — Nashville, Tennessee
Recruiting Industry
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…
Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Tennessee: - Research Site — Chattanooga, Tennessee
NA Recruiting Academic/Other
The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other m…
Sponsor: University of Tennessee
NCT ID: NCT03686709
Sites in Tennessee: - University of Tennessee Medical Center — Knoxville, Tennessee